[Methotrexate in the Therapy of Juvenile Idiopathic Arthritis]

Overview

Journal Z Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2010 Jul 16

PMID 20632181

Citations 4

Authors

D Holzinger

M Frosch

D Foll

Affiliations

Soon will be listed here.

Abstract

Treatment with low-dose methotrexate (MTX) is an important element in the therapy of juvenile idiopathic arthritis (JIA). It could be demonstrated in placebo-controlled trials that MTX is a safe and effective drug which is generally well tolerated by children and adolescents. MTX is usually used at a dose of 10-15 mg/m(2)/week, whereby oral administration is preferred for children. Side effects occur mainly in the form of gastro-intestinal discomfort such as nausea and vomiting or raised transaminases, which can be effectively treated with folic-acid supplementation.There are no general recommendations to date regarding in particular duration and discontinuation of MTX treatment or combination treatment with other disease-modifying antirheumatic drugs or biologics. These unresolved questions are the subject of current trials in which biomarkers have an increasingly important role.

Citing Articles

An improved understanding of pediatric chronic nonbacterial osteomyelitis pathophysiology informs current and future treatment.

Roberts E, Charras A, Hahn G, Hedrich C J Bone Miner Res. 2024; 39(11):1523-1538.

PMID: 39209330 PMC: 11523093. DOI: 10.1093/jbmr/zjae141.

Treatment and monitoring of SAPHO syndrome: a systematic review.

Li S, Roberts E, Hedrich C RMD Open. 2023; 9(4).

PMID: 38151265 PMC: 10753757. DOI: 10.1136/rmdopen-2023-003688.

A rare side effect of methotrexate therapy: drug-induced osteopathy with multiple fractures of the lower limb.

Singh D, Hesse N, Skapenko A, Schulze-Koops H RMD Open. 2023; 9(1).

PMID: 36810186 PMC: 9945041. DOI: 10.1136/rmdopen-2023-002982.

Predictors of response to methotrexate in juvenile idiopathic arthritis.

Albarouni M, Becker I, Horneff G Pediatr Rheumatol Online J. 2014; 12:35.

PMID: 25143761 PMC: 4138941. DOI: 10.1186/1546-0096-12-35.

References

Nixon R, Bansback N, Brennan A . The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford). 2007; 46(7):1140-7. DOI: 10.1093/rheumatology/kem072. View

Cleary A, McDowell H, Sills J . Polyarticular juvenile idiopathic arthritis treated with methotrexate complicated by the development of non-Hodgkin's lymphoma. Arch Dis Child. 2002; 86(1):47-9. PMC: 1719052. DOI: 10.1136/adc.86.1.47. View

Bartoli M, Taro M, Magni-Manzoni S, Pistorio A, Traverso F, Viola S . The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2007; 67(3):370-4. DOI: 10.1136/ard.2007.073445. View

Cespedes-Cruz A, Gutierrez-Suarez R, Pistorio A, Ravelli A, Loy A, Murray K . Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. Ann Rheum Dis. 2007; 67(3):309-14. DOI: 10.1136/ard.2007.075895. View

Singh G, Fries J, Williams C, Zatarain E, Spitz P, Bloch D . Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol. 1991; 18(2):188-94. View

Shaikov A, Maximov A, SPERANSKY A, Lovell D, Giannini E, Solovyev S . Repetitive use of pulse therapy with methylprednisolone and cyclophosphamide in addition to oral methotrexate in children with systemic juvenile rheumatoid arthritis--preliminary results of a longterm study. J Rheumatol. 1992; 19(4):612-6. View

Kremer J, Galivan J, Streckfuss A, Kamen B . Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum. 1986; 29(7):832-5. DOI: 10.1002/art.1780290703. View

Ruperto N, Lovell D, Quartier P, Paz E, Rubio-Perez N, Silva C . Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010; 62(6):1792-802. DOI: 10.1002/art.27431. View

Ruperto N, Murray K, Gerloni V, Wulffraat N, Knupp Feitosa de Oliveira S, Falcini F . A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004; 50(7):2191-201. DOI: 10.1002/art.20288. View

10.

Guellac N, Niehues T . [Interdisciplinary and evidence-based treatment guideline for juvenile idiopathic arthritis]. Klin Padiatr. 2008; 220(6):392-402. DOI: 10.1055/s-0028-1086037. View

11.

Bawle E, Conard J, WEISS L . Adult and two children with fetal methotrexate syndrome. Teratology. 1998; 57(2):51-5. DOI: 10.1002/(SICI)1096-9926(199802)57:2<51::AID-TERA2>3.0.CO;2-9. View

12.

Ravelli A, Migliavacca D, Viola S, Ruperto N, Pistorio A, Martini A . Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol. 1999; 17(5):625-7. View

13.

Krugmann J, Sailer-Hock M, Muller T, Gruber J, Allerberger F, Offner F . Epstein-Barr virus-associated Hodgkin's lymphoma and legionella pneumophila infection complicating treatment of juvenile rheumatoid arthritis with methotrexate and cyclosporine A. Hum Pathol. 2000; 31(2):253-5. DOI: 10.1016/s0046-8177(00)80230-0. View

14.

Giannini E, Brewer E, Kuzmina N, Shaikov A, Maximov A, Vorontsov I . Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med. 1992; 326(16):1043-9. DOI: 10.1056/NEJM199204163261602. View

15.

Oguey D, Kolliker F, Gerber N, Reichen J . Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1992; 35(6):611-4. DOI: 10.1002/art.1780350603. View

16.

Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J . Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 2002; 99(11):3909-15. DOI: 10.1182/blood.v99.11.3909. View

17.

Huang J . Methotrexate in the treatment of children with chronic arthritis--long-term observations of efficacy and safety. Br J Clin Pract. 1996; 50(6):311-4. View

18.

Weinblatt M, Kremer J, Bankhurst A, Bulpitt K, Fleischmann R, Fox R . A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999; 340(4):253-9. DOI: 10.1056/NEJM199901283400401. View

19.

Lovell D, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K . Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008; 359(8):810-20. DOI: 10.1056/NEJMoa0706290. View

20.

Jundt J, Browne B, Fiocco G, Steele A, Mock D . A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol. 1993; 20(11):1845-9. View